Announcements Trials

Browse Landscape

Phase

Status

Completed 15 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms 1 Metastatic Urothelial Cell Cancer 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 HER-2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma 1

Interventions

Gemcitabine 34 pembrolizumab 26 Paclitaxel 21 Cyclophosphamide 21 Docetaxel 20 Carboplatin 20 Irinotecan 19 Capecitabine 19 Fluorouracil 17 Bevacizumab 15 Dexamethasone 14 fludarabine 13 Oxaliplatin 13 Leucovorin 13 Blood Specimen Collection 13 Everolimus 12 Cetuximab 12 Ipilimumab 11 Erlotinib Hydrochloride 11 Rituximab 10 Pemetrexed 10 Cisplatin 10 venetoclax 9 Temozolomide 9 Sunitinib 9 Nivolumab 9 Trastuzumab 8 Interleukin-2 8 aldesleukin 7 Epoetin Alfa 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × eribulin × Clear all

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡